Antitumor combinations containing a VEGF inhibitor and 5FU or one of its derivatives

Details for Australian Patent Application No. 2005311191 (hide)

International Classifications

Event Publications

28 June 2007 PCT application entered the National Phase

PCT publication WO2006/059012 Priority application(s): WO2006/059012

8 December 2011 Application Accepted

Published as AU-B-2005311191

2 February 2012 Section 223 Application Allowed

Aventis Pharma S.A. The time in which to pay the response fees has been extended to 21 Jan 2012. Address for service in Australia - A J PARK Level 11 60 Marcus Clarke Street Canberra ACT 2601 2007

2 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under reg. 22.2E(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

5 April 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.